Vol 71, No 3 (2020)
Clinical vignette
Published online: 2020-03-10

open access

Page views 1194
Article views/downloads 903
Get Citation

Connect on Social Media

Connect on Social Media

Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer

Havva Sezer1, Dilek Yazıcı1, Oğuzhan Deyneli1, Çişel Meriçöz1, Ayla Esin1, Emrah Alper1
Pubmed: 32154575
Endokrynol Pol 2020;71(3):283-284.

Abstract

Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file

References

  1. U.S. Food and Drug Administration. FDA Adverse Events Reporting System — Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System 2019.
  2. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393(10166): 31–39.
  3. Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab. 2018; 20(1): 25–33.
  4. Limenta M, Ho CSC, Poh JWW, et al. Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors. Clin Drug Investig. 2019; 39(7): 683–690.
  5. Markabawi D, Kondapi D, Tambe V, et al. When it is not just DKA; diabetic ketoacidosis as a first presentation of pancreatic adenocarcinoma. Am J Emerg Med. 2018; 36(9): 1720.e1–1720.e2.